CD274 and cancer: Remarkably, the glyco-engineered anti-PD-L1 induced enhanced CD8 T cell activation in a mixed leukocyte reaction (MLR) determined by expression of activation markers, proliferation, and cytotoxicity against cancer cells, suggesting an improved therapeutic benefit.